Evaluating anticancer drug therapies for gynecologic and breast cancers
Official title: Observational Study Evaluating the Efficacy and Tolerability of Anticancer Drug Therapies Adopted for the Treatment of Gynecologic and Breast Cancers in Clinical Practice Compared with the Results of Registration Studies
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06800612 · Data updated 2026-11-12
This study is testing different cancer drug treatments to see how well they work and how well patients with breast and gynecologic cancers can tolerate them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Status | Recruiting |
| Started | March 22, 2024 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | January 30, 2025 |
| Trial ID | NCT06800612 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with histologically confirmed early-stage or metastatic breast cancer or gynecologic cancer who have received treatment since January 2010.
✕Probably not a fit
Patients who have not been diagnosed with breast or gynecologic cancers or those who have not received treatment since January 2010 may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the efficacy and tolerability of various anticancer drug therapies in patients with breast and gynecologic cancers. It will evaluate outcomes such as objective responses, disease-free survival, progression-free survival, overall survival, and side effects by comparing data with existing registry studies. The study includes both retrospective and prospective components, with therapy being administered as per standard clinical practice. Patients enrolled will not undergo additional examinations beyond routine diagnostic investigations.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness and safety of anticancer therapies for breast and gynecologic cancers, potentially improving treatment strategies.
How similar studies have gone: Other studies have shown success in evaluating anticancer therapies, indicating that this approach is supported by existing research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic; * Patients who have received treatment for breast cancer or gynecologic cancer since January 2010; * Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data. Exclusion Criteria: * no exclusion criteria
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy Recruiting
Study contacts
- Principal investigator: Claudio Zamagni, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola
- Study coordinator: Claudio Zamagni, MD
- Email: zamagniclaudio.sper@aosp.bo.it
- Phone: 0512144548
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
-
ARR-002 in advanced ovarian or endometrial cancer
This phase 1 study tests ARR-002 to see if it is safe and tolerable in adults with advanced or metastatic ovarian or endometrial cancer who have limited treatment options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.